Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF2R | P11717 | 5/20 | 0.85 |
| ▸ | FBP1 | P09467 | 1/20 | 0.54 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.47 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.47 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | AMDHD2 | Q9Y303 | 1/20 | 0.44 |
| ▸ | TLR4 | O00206 | 1/20 | 0.44 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.43 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.43 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.43 |
| ▸ | GBA1 | P04062 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7995162 | 1.00 | IGF2R (0.85) | IGF2RFBP1LPAR3LPAR1LPAR2 | |
| SCHEMBL7993492 | 0.95 | IGF2R (0.80) | IGF2RFBP1MAPK1AMDHD2TLR4 | |
| SCHEMBL7980720 | 0.89 | IGF2R (0.74) | IGF2RFBP1AMDHD2 | |
| SCHEMBL28098088 | 0.87 | IGF2R (0.64) | IGF2RFBP1LPAR3LPAR1LPAR2 | |
| SCHEMBL19660846 | 0.85 | IGF2R (0.76) | IGF2RFBP1MAPK1AMDHD2LGALS8 | |
| SCHEMBL19929291 | 0.84 | IGF2R (0.67) | IGF2RFBP1AMDHD2 | |
| SCHEMBL2615799 | 0.84 | IGF2R (0.75) | IGF2RFBP1MAPK1AMDHD2LGALS8 | |
| SCHEMBL933188 | 0.84 | IGF2R (0.75) | IGF2RFBP1MAPK1AMDHD2LGALS8 | |
| SCHEMBL21470012 | 0.83 | IGF2R (0.78) | IGF2RFBP1AMDHD2LGALS8LGALS3 | |
| SCHEMBL19509824 | 0.83 | IGF2R (0.78) | IGF2RFBP1AMDHD2LGALS8LGALS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2192924-B1 | SACCHARIDE-CONTAINING PROTEIN CONJUGATES AND USES THEREOF | PROTALIX LTD (IL) | 2017-10-11 | — | — | EP | disclosed |
| US-20140256017-A1 | SACCHARIDE-CONTAINING PROTEIN CONJUGATES AND USES THEREOF | PROTALIX LTD. (IL) | 2014-09-11 | — | — | US | disclosed |
| US-8742079-B2 | Saccharide-containing protein conjugates and uses thereof | PROTALIX LTD. (IL) | 2014-06-03 | — | — | US | disclosed |
| US-20110105379-A1 | SACCHARIDE-CONTAINING PROTEIN CONJUGATES AND USES THEREOF | PROTALIX LTD. (IL) | 2011-05-05 | — | — | US | disclosed |
| EP-2192924-A2 | SACCHARIDE-CONTAINING PROTEIN CONJUGATES AND USES THEREOF | Protalix Ltd. (IL) | 2010-06-09 | — | — | EP | disclosed |
| WO-2009024977-A2 | SACCHARIDE-CONTAINING PROTEIN CONJUGATES AND USES THEREOF | PROTALIX LTD. (IL) | 2009-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256017-A1 | SACCHARIDE-CONTAINING PROTEIN CONJUGATES AND USES THEREOF | STT3B, STT3A, DDOST | IGF2R 295/4885FBP1 527/4885LPAR3 4481/4885 |
| US-20110105379-A1 | SACCHARIDE-CONTAINING PROTEIN CONJUGATES AND USES THEREOF | STT3B, STT3A, DDOST | IGF2R 295/4885FBP1 527/4885LPAR3 4481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.